Book a demo

Chemical intelligence powered by cypris.ai

Undecaprenol

(2E,6E,10E,14E,18E,22E,26E,30E,34E,38E)-3,7,11,15,19,23,27,31,35,39,43-undecamethyltetratetraconta-2,6,10,14,18,22,26,30,34,38,42-undecaen-1-ol · also: C55 Prenol, Ficaprenol, Ficaprel 11, Moraprenol 11, all-trans-undecaprenol, 3,7,11,15,19,23,27,31,35,39,43-undecamethyltetratetraconta-2E,6E,10E,14E,18E,22E,26E,30E,34E,38E,42-undecaen-1-ol

FormulaC55H90O
Mol. weight767.324
PubChem CID5280474
InChIKeyTXKJNHBRVLCYFX-RDQGWRCRSA-N
SMILESCC(=CCC/C(=C/CC/C(=C/CC/C(=C/CC/C(=C/CC/C(=C/CC/C(=C/CC/C(=C/CC/C(=C/CC/C(=C/CC/C(=C/CO)/C)/C)/C)/C)/C)/C)/C)/C)/C)/C)C
416Patents
21Research papers
43Patents - last 3 years
1Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#AssigneePatents
1GlaxoSmithKline Biologicals SA55
2Eisai Co Ltd20
3Cornell University14
4Nisshin Seifun Group Inc13
5Janssen Pharmaceuticals Inc12
6Purdue Research Foundation12
7North Carolina State University11
8Toyota Motor Corp11
9University of Iowa Research Foundation11
10AstraZeneca AB10

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#CodeAreaPatents
1A61KMedicinal preparations230
2C07KPeptides177
3A61PTherapeutic activity (drug indications)175
4C12NMicroorganisms, enzymes165
5Y02AClimate change adaptation91
6C12PFermentation, enzyme processes87
7C12YEnzyme nomenclature (EC numbers)60
8C12QMeasuring/testing involving enzymes55
9C12R34
10G01NInvestigating / analysing materials32

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Most-cited patents

Patents ranked by forward citations reveal the foundational inventions the field continues to build on.

TitleYearAssigneeCited by
Use of undecaprenol kinase inhibitors to inhibit cell wall biosynthesis2001ユニバーシティー オブ フロリダ0
USE OF INHIBITORS OF UNDECAPRENOL KINASE TO INHIBIT CELL WALL BIOSYNTHESIS2000University of Florida0
USE OF INHIBITORS OF UNDECAPRENOL KINASE TO INHIBIT CELL WALL BIOSYNTHESIS1998University of Florida0
Use of inhibitors of undecaprenol kinase to inhibit cell wall biosynthesis1998University of Florida0

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#AuthorAffiliationPapers
1Dominique Mengin‐LecreulxInstitut de Biochimie et Biophysique Moléculaire et Cellulaire2
2Frederic A. TroyUniversity of California, Davis2
3Mary OsbornUConn Health2
4Tadeusz ChojnackiPolish Academy of Sciences2
5Adrien DucretLyon 1 Université1
6Ahmed BouhssInstitut de Biochimie et Biophysique Moléculaire et Cellulaire1
7Amy E. TrunkfieldUniversity of Warwick1
8Anna MüllerUniversity of Bonn1
9Barbara C. McGrathUConn Health1
10Bruce E. Holbein1

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular formula and weight of undecaprenol?

Undecaprenol has the molecular formula C55H90O with a molecular weight of 767.324 g/mol. It is also known by several synonyms including C55 Prenol, Ficaprenol, and all-trans-undecaprenol.

Which organizations hold the most patents related to undecaprenol?

GlaxoSmithKline Biologicals SA is the leading patent assignee with 55 patents, followed by Eisai Co Ltd with 20 patents and Cornell University with 14 patents. Other significant patent holders include Nisshin Seifun Group Inc, Janssen Pharmaceuticals Inc, Purdue Research Foundation, North Carolina State University, Toyota Motor Corp, University of Iowa Research Foundation, and AstraZeneca AB.

What is the primary research focus of published papers on undecaprenol?

The research literature on undecaprenol focuses heavily on lipid membrane structure and behavior, with notable papers examining translocation of lipopolysaccharides, NMR investigation of polyisoprenol organization in membranes, and quantitative analysis of undecaprenyl phosphate pools in bacterial membranes. Additional research addresses bacterial genetics and undecaprenol kinase activity.

What patent classifications are most common for undecaprenol-related inventions?

The most prevalent patent classifications are A61K (230 patents) covering pharmaceutical formulations, C07K (177 patents) for organic chemistry, and A61P (175 patents) for pharmaceutical use. Biotechnology and genetic engineering classifications including C12N and C12P are also heavily represented with 165 and 87 patents respectively.

How has patent activity for undecaprenol evolved in recent years?

Patent activity shows significant variation, with 43 patents filed in the last three years. Recent years show peaks in 2023 with 21 patents and 2025 with 19 patents, though 2024 had only 13 patents and 2021 had only 6 patents. Paper publications on undecaprenol remain limited, with only 1 paper in the last three years out of 21 total papers in the database.

Turn any compound into a complete chemical intelligence landscape

Go beyond static compound data. Cypris resolves identities, patents, papers, and commercial signals into one AI-powered view - so your team can move from a single chemical question to a complete R&D, IP, and market landscape.

Schedule a free trial